Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: Analysis of SEAS and JUPITER trials

A. Poli, A. Corsini

Research output: Contribution to journalArticle

Abstract

A number of clinical trials have confirmed that statin treatment and, more generally, LDL-lowering treatment, are able to reduce CHD and CVD events in a wide range of clinical conditions associated with increased cardiovascular risk. However, the most recent trials have also identified patient groups in which lipid-lowering treatment shows a more limited preventive potential due to the "non-reversibility" of part of the cardiovascular risk, which dilutes the observed treatment effect by events that are not directly a consequence of atherosclerosis. The use of lipid-lowering therapy in these patients should be driven not only by their absolute risk, as suggested by the most recent American and European guidelines, but also by their overall clinical setting and by the evidence of benefit obtained in controlled trials in comparable populations.

Original languageEnglish
Pages (from-to)372-373
Number of pages2
JournalEuropean Journal of Internal Medicine
Volume21
Issue number5
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Lipids
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atherosclerosis
Clinical Trials
Guidelines
Population

Keywords

  • Atherosclerosis
  • Ezetimibe
  • Lipid-lowering drugs
  • Statins

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy : Analysis of SEAS and JUPITER trials. / Poli, A.; Corsini, A.

In: European Journal of Internal Medicine, Vol. 21, No. 5, 10.2010, p. 372-373.

Research output: Contribution to journalArticle

@article{ee04fdc5eabd44c183f756ace70ac46e,
title = "Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: Analysis of SEAS and JUPITER trials",
abstract = "A number of clinical trials have confirmed that statin treatment and, more generally, LDL-lowering treatment, are able to reduce CHD and CVD events in a wide range of clinical conditions associated with increased cardiovascular risk. However, the most recent trials have also identified patient groups in which lipid-lowering treatment shows a more limited preventive potential due to the {"}non-reversibility{"} of part of the cardiovascular risk, which dilutes the observed treatment effect by events that are not directly a consequence of atherosclerosis. The use of lipid-lowering therapy in these patients should be driven not only by their absolute risk, as suggested by the most recent American and European guidelines, but also by their overall clinical setting and by the evidence of benefit obtained in controlled trials in comparable populations.",
keywords = "Atherosclerosis, Ezetimibe, Lipid-lowering drugs, Statins",
author = "A. Poli and A. Corsini",
year = "2010",
month = "10",
doi = "10.1016/j.ejim.2010.04.013",
language = "English",
volume = "21",
pages = "372--373",
journal = "European Journal of Internal Medicine",
issn = "0953-6205",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy

T2 - Analysis of SEAS and JUPITER trials

AU - Poli, A.

AU - Corsini, A.

PY - 2010/10

Y1 - 2010/10

N2 - A number of clinical trials have confirmed that statin treatment and, more generally, LDL-lowering treatment, are able to reduce CHD and CVD events in a wide range of clinical conditions associated with increased cardiovascular risk. However, the most recent trials have also identified patient groups in which lipid-lowering treatment shows a more limited preventive potential due to the "non-reversibility" of part of the cardiovascular risk, which dilutes the observed treatment effect by events that are not directly a consequence of atherosclerosis. The use of lipid-lowering therapy in these patients should be driven not only by their absolute risk, as suggested by the most recent American and European guidelines, but also by their overall clinical setting and by the evidence of benefit obtained in controlled trials in comparable populations.

AB - A number of clinical trials have confirmed that statin treatment and, more generally, LDL-lowering treatment, are able to reduce CHD and CVD events in a wide range of clinical conditions associated with increased cardiovascular risk. However, the most recent trials have also identified patient groups in which lipid-lowering treatment shows a more limited preventive potential due to the "non-reversibility" of part of the cardiovascular risk, which dilutes the observed treatment effect by events that are not directly a consequence of atherosclerosis. The use of lipid-lowering therapy in these patients should be driven not only by their absolute risk, as suggested by the most recent American and European guidelines, but also by their overall clinical setting and by the evidence of benefit obtained in controlled trials in comparable populations.

KW - Atherosclerosis

KW - Ezetimibe

KW - Lipid-lowering drugs

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=77956408633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956408633&partnerID=8YFLogxK

U2 - 10.1016/j.ejim.2010.04.013

DO - 10.1016/j.ejim.2010.04.013

M3 - Article

C2 - 20816586

AN - SCOPUS:77956408633

VL - 21

SP - 372

EP - 373

JO - European Journal of Internal Medicine

JF - European Journal of Internal Medicine

SN - 0953-6205

IS - 5

ER -